03:00 Fri 05 Jun 2020
C4X Discovery - Clive Dix appointed to the UK Vaccine Taskforce
("C4XD", "
Government's taskforce to lead
Clive remains committed to delivering C4XD's strategy and this appointment will not impact his day-to-day role as CEO.
"We are very proud that Clive has been appointed to this important and prestigious taskforce. COVID-19 has had such a devastating impact not only in the
- Ends -
Contacts
|
|
|
+44 (0)787 6444977 |
|
|
|
|
|
+44 (0)20 7886 2500 |
|
|
|
|
C4X Discovery Media - |
|
|
+44 (0)203 709 5700 |
Notes to Editors:
About the
The Taskforce is supporting efforts to develop a COVID-19 vaccine as soon as possible by providing industry and research institutions with the resources and support needed. This includes working with regulators and scaling up manufacturing, so that when a vaccine is identified, it can be produced quickly and at scale.
About
C4XD has a state-of-the-art suite of proprietary technologies across the Drug Discovery process and accesses further innovative capabilities and expertise through its growing network of partners. The Company is actively advancing its diverse pre-clinical discovery portfolio which is focused on inflammation, neurodegeneration and oncology (including immuno-oncology). Opportunities to maximise value from the portfolio are proactively driven by C4XD's commercial division. The Company is led by a highly experienced management team and Board who have delivered significant value creation within the healthcare sector.
For additional information please go to: www.c4xdiscovery.com
This information is provided by RNS, the news service of the
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE